{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:36:07Z","timestamp":1793284567237,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ard.2026.08.020","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:15:03Z","timestamp":1790136903000},"page":"2233-2240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8416-3955","authenticated-orcid":false,"given":"Mats","family":"Junek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quazi","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eswari","family":"Vilayur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Fairhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Massicotte-Azarniouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pagnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Khalidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ard.2026.08.020_bib0001","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/rheumatology\/keaa667","article-title":"Prevalence and risk factors of relapse in patients with ANCA-associated vasculitis receiving cyclophosphamide induction: a systematic review and meta-analysis of large observational studies","volume":"60","author":"He","year":"2021","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"10.1016\/j.ard.2026.08.020_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ekir.2019.10.005","article-title":"Relapse in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis","volume":"5","author":"Salama","year":"2020","journal-title":"Kidney Int Rep."},{"issue":"8","key":"10.1016\/j.ard.2026.08.020_bib0003","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.ard.2026.08.020_bib0004","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1161\/STROKEAHA.107.501825","article-title":"Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation","volume":"39","year":"2008","journal-title":"Stroke."},{"issue":"9","key":"10.1016\/j.ard.2026.08.020_bib0005","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1002\/art.23800","article-title":"Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody\u2013associated small-vessel vasculitis: comparison of two independent cohorts","volume":"58","author":"Pagnoux","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.ard.2026.08.020_bib0006","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.ard.2026.08.020_bib0007","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/rheumatology\/keaa541","article-title":"Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models","volume":"60","author":"McClure","year":"2021","journal-title":"Rheumatology (Oxford)."},{"issue":"7","key":"10.1016\/j.ard.2026.08.020_bib0008","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.ard.2026.08.020_bib0009","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.42843","article-title":"Risk of relapse of antineutrophil cytoplasmic antibody-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids","volume":"76","author":"Junek","year":"2024","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.ard.2026.08.020_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-6215-14-73","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial","volume":"14","author":"Walsh","year":"2013","journal-title":"Trials."},{"issue":"4","key":"10.1016\/j.ard.2026.08.020_bib0011","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.ard.2026.08.020_bib0012","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the Cox model with cumulative sums of martingale-based residuals","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika."},{"issue":"19","key":"10.1016\/j.ard.2026.08.020_bib0013","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.ard.2026.08.020_bib0014","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","article-title":"The lasso method for variable selection in the Cox model","volume":"16","author":"Tibshirani","year":"1997","journal-title":"Stat Med."},{"issue":"4","key":"10.1016\/j.ard.2026.08.020_bib0015","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med."},{"issue":"10","key":"10.1016\/j.ard.2026.08.020_bib0016","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med."},{"issue":"1","key":"10.1016\/j.ard.2026.08.020_bib0017","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/M22-0844","article-title":"Assessing performance and clinical usefulness in prediction models with survival outcomes: practical guidance for Cox proportional hazards models","volume":"176","author":"McLernon","year":"2023","journal-title":"Ann Intern Med."},{"issue":"12","key":"10.1016\/j.ard.2026.08.020_bib0018","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1177\/09622802221122391","article-title":"Modified Brier score for evaluating prediction accuracy for binary outcomes","volume":"31","author":"Yang","year":"2022","journal-title":"Stat Methods Med Res."},{"issue":"1","key":"10.1016\/j.ard.2026.08.020_bib0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"issue":"3","key":"10.1016\/j.ard.2026.08.020_bib0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/1467-9876.00155","article-title":"The use of resampling methods to simplify regression models in medical statistics","volume":"48","author":"Sauerbrei","year":"1999","journal-title":"J R Stat Soc Ser C Appl Stat."},{"issue":"446","key":"10.1016\/j.ard.2026.08.020_bib0021","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ard.2026.08.020_bib0022","doi-asserted-by":"crossref","first-page":"g7594","DOI":"10.1136\/bmj.g7594","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"350","author":"Collins","year":"2015","journal-title":"BMJ."},{"issue":"7","key":"10.1016\/j.ard.2026.08.020_bib0023","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"19","key":"10.1016\/j.ard.2026.08.020_bib0024","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.ard.2026.08.020_bib0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med."},{"issue":"7","key":"10.1016\/j.ard.2026.08.020_bib0026","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/art.39614","article-title":"Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease","volume":"68","author":"Rhee","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.ard.2026.08.020_bib0027","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/art.39637","article-title":"Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3","volume":"68","author":"Fussner","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.ard.2026.08.020_bib0028","doi-asserted-by":"crossref","first-page":"rkab018","DOI":"10.1093\/rap\/rkab018","article-title":"Predicting relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic review and meta-analysis","volume":"5","author":"King","year":"2021","journal-title":"Rheumatol Adv Pract."},{"key":"10.1016\/j.ard.2026.08.020_bib0029","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10792-007-9109-y","article-title":"Diagnosis of limited ophthalmic Wegener granulomatosis: distinctive pathologic features with ANCA test confirmation","volume":"28","author":"Ahmed","year":"2008","journal-title":"Int Ophthalmol."},{"issue":"2","key":"10.1016\/j.ard.2026.08.020_bib0030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00296-019-04406-5","article-title":"The complexity of classifying ANCA-associated small-vessel vasculitis in actual clinical practice: data from a multicenter retrospective survey","volume":"40","author":"Corral-Gudino","year":"2020","journal-title":"Rheumatol Int."},{"issue":"1","key":"10.1016\/j.ard.2026.08.020_bib0031","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.27763","article-title":"Improved outcome in 445 patients with Wegener\u2019s granulomatosis in a German vasculitis center over four decades","volume":"63","author":"Holle","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.ard.2026.08.020_bib0032","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-017-1321-1","article-title":"Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse","volume":"19","author":"Morgan","year":"2017","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"10.1016\/j.ard.2026.08.020_bib0033","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis\u2013a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"10.1016\/j.ard.2026.08.020_bib0034","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2023-224489","article-title":"Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial","volume":"83","author":"Zonozi","year":"2024","journal-title":"Ann Rheum Dis."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726005455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726005455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:06:46Z","timestamp":1793282806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726005455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0003496726005455"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.08.020","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}